Pravastatin for prevention of HELLP syndrome: A case report.
Pravastatin for prevention of HELLP syndrome: A case report.
复制标题
DOI：
10.1097/md.0000000000008229
复制
发表时间：
2017-10
期刊：
影响因子：
1.6
通讯作者：
Merz WM
中科院分区：
文献类型：
--
作者：
Otten LA;van der Ven K;Kühr M;Gembruch U;Merz WM
普伐他汀已经出现用于预防和治疗先兆子痫;没有关于普伐他汀和HELLP（溶血、肝酶升高和血小板减少）综合征的报告。第一次怀孕需要终止妊娠的胎龄（GA）20+5 HELLP。在第二次妊娠中，在HELLP的临时管理中发生了GA 22+5的宫内胎儿死亡。重度复发性早发性HELLP综合征。在她的第四次妊娠中，普伐他汀在GA 13开始。妊娠过程不复杂，足月分娩的胎儿健康，适合胎龄。普伐他汀可能对HELLP的预防有效。肝摄取可能特别有利。
Pravastatin has emerged for prevention and treatment of preeclampsia; no reports are available on pravastatin and HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome. The first pregnancy necessitated termination of pregnancy at gestational age (GA) 20+5 for HELLP. Intrauterine fetal death at GA 22+5 occurred in the second pregnancy, whilst on temporizing management of HELLP. Severe, recurrent early-onset HELLP syndrome. In her fourth pregnancy, pravastatin was commenced at GA 13. The course of pregnancy was uncomplicated, and a healthy, appropriate for gestational age fetus was delivered at term. Pravastatin may be effective in prevention of HELLP. The hepatic uptake may be of particular advantage.